History in Brief
Dyax was co-founded in 1995 by biotechnology entrepreneur Henry E. Blair, who served as director and Chief Executive Officer until December 31, 2008. After transitioning his executive role to Gustav Christensen, Mr. Blair continues to serve Dyax as Chairman of the Board.
Our company was formed by the merger of Biotage, a separations instrument chromatography firm, and Protein Engineering Corporation, from which we acquired our patented phage display technology. In 2003, we sold our non-core business, Biotage, to focus exclusively on the discovery and development of biotherapeutics.
Dyax issued an initial public offering (IPO) in August 2000 and is listed on the NASDAQ exchange (Ticker: DYAX).